Characteristics of IV plerixafor-mobilized apheresis products, phase 2
| Characteristic . | Mean (range) . |
|---|---|
| Viability of product, % | 93 (87-99) |
| Length of product storage, d | 24 (6-241) |
| Peak mobilized CD34/μL, phase 1 | 28.7 (7-157) |
| Peak mobilized CD34/μL, phase 2 | 18.6 (4-46) |
| Total no. CD34 collected day 1 × 108 | 2.1 (0.5-6.6) |
| Pheresis volume day 1, L | 17.91 (3.7-20) |
| No. CD3 × 108/kg recipient weight | 5.25 (1.98-10) |
| No. CD34 × 106/kg recipient weight | 2.9 × 106 (2.0-9.7 × 106) |
| Characteristic . | Mean (range) . |
|---|---|
| Viability of product, % | 93 (87-99) |
| Length of product storage, d | 24 (6-241) |
| Peak mobilized CD34/μL, phase 1 | 28.7 (7-157) |
| Peak mobilized CD34/μL, phase 2 | 18.6 (4-46) |
| Total no. CD34 collected day 1 × 108 | 2.1 (0.5-6.6) |
| Pheresis volume day 1, L | 17.91 (3.7-20) |
| No. CD3 × 108/kg recipient weight | 5.25 (1.98-10) |
| No. CD34 × 106/kg recipient weight | 2.9 × 106 (2.0-9.7 × 106) |